In the latest bid to address high prescription drug costs, a nonprofit plans to sell a cheaper generic version of an expensive cancer medicine in the U.S.
Civica Rx, which was formed four years ago, is working with a generic manufacturer, Hikma Pharmaceuticals, to supply pharmacies with the abiraterone prostate cancer treatment for $160 for a month’s supply. And the nonprofit is suggesting pharmacies sell the medicine to consumers for $171, which is considerably less than what most consumers currently pay. The brand-name version is Zytiga.
By comparison, Medicare Part D beneficiaries, who are believed to make up the majority of consumers prescribed existing generic versions, pay about $3,200 a month, although prices do vary. Using a coupon, a consumer could pay $187 a month at the Rite Aid retail chain, but the medicine would cost close to $3,000 at several chains, according to the GoodRx website. In some cases, cash-paying customers may pay $250 or more.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect